Filing Flows › Anika Therapeutics (ANIK) › Who owns the stock
Who owns Anika Therapeutics (ANIK) stock
133 funds reported Anika Therapeutics (ANIK) shares in their latest 13F filings, worth $191M in all. The largest holder is BlackRock ($21.2M). Last quarter 62 funds added to their stakes and 47 cut them.
Largest holders (13F)
| Fund | Shares | Value | Change | Quarter |
|---|---|---|---|---|
| BlackRock | 1,449,671 | $21.2M | decrease | 2026-06-30 |
| Caligan Partners LP | 1,435,130 | $21.0M | unchanged | 2026-06-30 |
| Morgan Stanley | 614,320 | $9.0M | decrease | 2026-06-30 |
| Acadian Asset Management LLC | 606,544 | $8.9M | unchanged | 2026-06-30 |
| Vanguard Capital Management LLC | 572,113 | $8.4M | decrease | 2026-06-30 |
| AQR Capital Management LLC | 559,846 | $8.2M | increase | 2026-06-30 |
| Boothbay Fund Management, LLC | 529,640 | $7.7M | increase | 2026-06-30 |
| Vanguard Group | 779,165 | $7.5M | decrease | 2025-12-31 |
| Capital Management | 379,436 | $7.5M | decrease | 2026-09-30 |
| Renaissance Technologies LLC | 481,417 | $7.0M | decrease | 2026-06-30 |
| Deutsche Bank Ag\ | 352,134 | $6.9M | decrease | 2026-09-30 |
| Dimensional Fund Advisors LP | 451,095 | $6.6M | decrease | 2026-06-30 |
| Geode Capital Management, LLC | 331,577 | $4.9M | increase | 2026-06-30 |
| State Street | 311,896 | $4.6M | decrease | 2026-06-30 |
| Two Sigma Investments, LP | 252,964 | $3.7M | increase | 2026-06-30 |
Anika Therapeutics' latest quarter
Anika Therapeutics, Q3 2026: revenue $30.6M (+10% year over year), operating margin -2.3%, net loss $311K, operating cash flow $8.4M. The chart follows the revenue to costs, profit and cash.
Questions
Who owns the most ANIK stock?
By the latest 13F filings: BlackRock ($21.2M); Caligan Partners LP ($21.0M); Morgan Stanley ($9.0M); Acadian Asset Management LLC ($8.9M); Vanguard Capital Management LLC ($8.4M).
What is the short interest in ANIK?
365,717 shares were sold short at the 2026-10-15 settlement, -0.39% of the float.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.